Reed Jobs would rather talk about curing cancer than his last name
When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in r
The story of Reed Jobs, son of the late Steve Jobs, highlights a significant shift in focus towards biotechnology and healthcare. As the founder of Yosemite, a venture firm investing in innovative technologies, Reed's efforts to cure cancer demonstrate a commitment to using technology for social impact. This move is particularly noteworthy given the current landscape of the biotech industry, which is experiencing a surge in activity as patents for blockbuster drugs expire, creating opportunities for new entrants and innovations.
The fact that Reed Jobs would rather discuss his work in cancer research than his famous last name suggests a desire to establish his own identity and legacy in the tech and biotech worlds. This is a significant development, as it indicates a new generation of tech leaders who are prioritizing meaningful applications of technology over mere prestige or recognition. The growth of Yosemite, from a new firm to a team of 17, also underscores the potential for venture capital to drive innovation in critical areas like healthcare.
As the biotech industry continues to evolve, it will be important to watch how firms like Yosemite navigate the intersection of technology and healthcare. With a cluster of blockbuster drugs losing patent protection, there may be opportunities for new treatments and therapies to emerge, driven by venture capital and innovative technologies. The work of Reed Jobs and Yosemite will be worth following, as it may provide insights into the future of biotech and the role of tech leaders in driving social impact through healthcare innovation.
Originally reported by techcrunch.com. URLNews adds analysis for ai & agent economy readers.